Illumina Appoints Matthew Posard to Lead Worldwide Marketing
News Feb 01, 2006
Illumina, Inc. has announced the appointment of Matthew L. Posard as Vice President of Marketing. Mr. Posard will be responsible for all worldwide strategic and tactical marketing for Illumina.
Mr. Posard has thirteen years of marketing, sales and service experience in the healthcare field, with particular expertise in the diagnostics industry. Most recently, he spent over six years in various sales and marketing director positions at Biosite Inc.
While at Biosite, Mr. Posard oversaw the commercialization of several novel products including the BNP (B-type natriuretic peptide) heart failure diagnostic test now used in over 50% of U.S. hospitals.
Prior to Biosite, Posard held various marketing positions at Gen-Probe, Inc. managing strategic marketing, new product planning, market research, project management, customer service and sales administration.
Posard received his B.A. degree in quantitative economics and decision science from the University of California, San Diego.
"Matt brings great commercialization experience and strong management skills to Illumina," said Jay Flatley, Illumina President and CEO.
"He has a proven ability to operate in regulated environments that we're targeting downstream of the research field, and we're very excited to have him join our senior leadership team."
Hay Fever Risk Genes Overlap with Autoimmune DiseaseNews
In a large international study involving almost 900,000 participants, researchers from the University of Copenhagen and COPSAC have found new risk genes for hay fever. It is the largest genetic study so far on this type of allergy, which affects millions of people around the world.READ MORE
Hidden Signals in RNAs Regulate Protein SynthesisNews
Scientists have long known that RNA encodes instructions to make proteins. In a new study published in Nature, scientists describe how the protein-making machinery identifies alternative initiation sites from which to start protein synthesis.READ MORE
ExPecto Patronum! Magical Machine Learning Tool Summons DNA Dark Matter DataNews
A new machine learning framework, dubbed ExPecto, can predict the effects of mutations in the so-called “dark matter” regions of the human genome. ExPecto pinpoints how mutations can disrupt the way genes turn on and off throughout your body.